Pharma channel feed – Endpoints News

Pharma channel feed

Teva’s migraine drug can’t stop another bad R&D headache as researchers scrap a failed PhIII program for Ajovy

7 years ago

As rivals wait in line, Merck's Keytruda scores early FDA nod for frontline patients with the most common form of kidney cancer

7 years ago

FDA approves the first generic for life-saving opioid overdose treatment naloxone that can be carried by untrained individuals

7 years ago

Industry calls for changes in two REMS guidances

7 years ago

Forget biosimilars. Peter Bach and Mark Trusheim believe price controls are the better way to rein in biologics prices

7 years ago

Amgen prices bone builder Evenity at $21,900/year to compete on convenience, not cost

7 years ago

FDA tells Sprout Pharma, like it or not the black box on Addyi stays, but we will dilute the warning

7 years ago

A blockbuster cocktail? Gilead slides Novo Nordisk's semaglutide into new NASH triple therapy

7 years ago

Braeburn petitions FDA to revoke Sublocade orphan designation

7 years ago

Regeneron, Alnylam spell out a research alliance that could run beyond a decade, with billions built in for success

7 years ago

In combat mode, Indivior hunkers down for a war with DoJ over multibillion-dollar fraud charges

7 years ago

FDA, Brigham and Women’s to test if RWE is ripe now for replacing clinical drug trials

7 years ago

Chinese player joins a growing group of biotechs buying into Synaffix's ADC linker tech

7 years ago

Compared to avoidance, Aimmune's peanut allergy treatment an improvement over DBV's product — ICER

7 years ago

As public furor mounts, Sanofi makes deep cuts to US insulin prices in savings program

7 years ago

Once spurned, Amgen wins the FDA over with its bone-building osteoporosis drug Evenity

7 years ago

Two Republican lawmakers feel 'obliged' to warn drugmakers that Democrat colleague Cummings is purportedly out to deflate their stock prices

7 years ago

BeiGene lines up a next-gen CTLA-4 to complement its PD-1 pillar in new deal worth up to $270M

7 years ago

PhaseBio touts 'breakthrough' badge for bloodthinner reversal agent licensed from AstraZeneca, shares leap

7 years ago

Battered and out of options, Histogenics turns to eye drug developer Ocugen for reverse merger

7 years ago

Celgene, Acceleron submit FDA application for billed blockbuster luspatercept — will they get priority review?

7 years ago

Going gangbusters: The top 20 biotech platform deals by upfront cash

7 years ago

At a cool $1B-plus in upfront, equity and early-stage cash, Regeneron ties a blockbuster R&D partnership knot with RNAi leader Alnylam

7 years ago

Jazz, Lundbeck and Alexion pay $122M+ to resolve DoJ claims of using charities as 'conduits' to stimulate use of their drugs

7 years ago

First page Previous page 271 272 273274275 276 277 Next page Last page